Association of nutritional risk index with metabolic biomarkers, appetite-regulatory hormones and inflammatory biomarkers and outcome in patients with chronic heart failure
2014; Wiley; Volume: 68; Issue: 11 Linguagem: Inglês
10.1111/ijcp.12513
ISSN1742-1241
AutoresGhazaleh Gouya, P. Voithofer, Stephanie Neuhold, Angela Storka, Greisa Vila, Richard Pacher, Michael Wolzt, Martin Hülsmann,
Tópico(s)Adipokines, Inflammation, and Metabolic Diseases
ResumoInternational Journal of Clinical PracticeVolume 68, Issue 11 p. 1293-1300 Original Paper Association of nutritional risk index with metabolic biomarkers, appetite-regulatory hormones and inflammatory biomarkers and outcome in patients with chronic heart failure G. Gouya, Corresponding Author G. Gouya Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria Correspondence to: Ghazaleh Gouya, MD, Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie, Waehringer Guertel 18-20, A-1090 Wien, Austria Tel.: +43 1 40400 2981 Fax: +43 1 40400 2998 Email: ghazaleh.gouya@meduniwien.ac.atSearch for more papers by this authorP. Voithofer, P. Voithofer Department of Clinical Pharmacology, Medical University Vienna, Vienna, AustriaSearch for more papers by this authorS. Neuhold, S. Neuhold Department of Innere Medizin II, Division of Cardiology, Medical University Vienna, Vienna, AustriaSearch for more papers by this authorA. Storka, A. Storka Department of Clinical Pharmacology, Medical University Vienna, Vienna, AustriaSearch for more papers by this authorG. Vila, G. Vila Department of Innere Medizin III, Division of Endocrinology and Metabolism, Medical University Vienna, Vienna, AustriaSearch for more papers by this authorR. Pacher, R. Pacher Department of Innere Medizin II, Division of Cardiology, Medical University Vienna, Vienna, AustriaSearch for more papers by this authorM. Wolzt, M. Wolzt Department of Clinical Pharmacology, Medical University Vienna, Vienna, AustriaSearch for more papers by this authorM. Hülsmann, M. Hülsmann Department of Innere Medizin II, Division of Cardiology, Medical University Vienna, Vienna, AustriaSearch for more papers by this author G. Gouya, Corresponding Author G. Gouya Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria Correspondence to: Ghazaleh Gouya, MD, Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie, Waehringer Guertel 18-20, A-1090 Wien, Austria Tel.: +43 1 40400 2981 Fax: +43 1 40400 2998 Email: ghazaleh.gouya@meduniwien.ac.atSearch for more papers by this authorP. Voithofer, P. Voithofer Department of Clinical Pharmacology, Medical University Vienna, Vienna, AustriaSearch for more papers by this authorS. Neuhold, S. Neuhold Department of Innere Medizin II, Division of Cardiology, Medical University Vienna, Vienna, AustriaSearch for more papers by this authorA. Storka, A. Storka Department of Clinical Pharmacology, Medical University Vienna, Vienna, AustriaSearch for more papers by this authorG. Vila, G. Vila Department of Innere Medizin III, Division of Endocrinology and Metabolism, Medical University Vienna, Vienna, AustriaSearch for more papers by this authorR. Pacher, R. Pacher Department of Innere Medizin II, Division of Cardiology, Medical University Vienna, Vienna, AustriaSearch for more papers by this authorM. Wolzt, M. Wolzt Department of Clinical Pharmacology, Medical University Vienna, Vienna, AustriaSearch for more papers by this authorM. Hülsmann, M. Hülsmann Department of Innere Medizin II, Division of Cardiology, Medical University Vienna, Vienna, AustriaSearch for more papers by this author First published: 02 September 2014 https://doi.org/10.1111/ijcp.12513Citations: 15 Disclosures: None. Linked Comment: Vincent. Int J Clin Pract 2014; 68: 1284–5. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Summary Aims We aimed to evaluate the association of the nutritional status by using the nutritional risk index (NRI) with metabolic and inflammatory biomarkers, and appetite-regulatory hormones in a cohort of stable patients with heart failure (HF), and to analyse its prognostic value. Methods and results In this prospective observational cohort study, we included 137 stable chronic HF patients (median age, 60 years; median body mass index, 27 kg/m2) with optimised medical treatment. Baseline NRI of < 113 (n = 45) was associated with a significant increase in the levels of ghrelin (p < 0.001), peptide YY (p = 0.007), pentraxin-3 (p = 0.001), tumour necrosis factor-alpha (p = 0.018), adiponectin (p < 0.0001) and the N-terminal prohormone of brain natriuretic peptide (NT-proBNP; p < 0.0001) compared with those in patients with NRI of ≥ 113. The NRI was found to be correlated with the homoeostasis model assessment of insulin resistance index (r = 0.444; p < 0.0001) and inversely correlated with the NT-proBNP level (r = −0.410; p < 0.0001). The overall mortality rate was 20%. A baseline NRI of < 113 was associated with a higher risk of all-cause mortality (log rank = 0.031). Conclusion We propose that the NRI is a useful and easily applicable tool for the early identification of nutritional depletion in patients with chronic HF as it discriminates metabolic changes prior to the clinical manifestation of body wasting. Furthermore, poor nutritional status, represented as a low NRI, is associated with an increased incidence of death in such cases. Citing Literature Volume68, Issue11November 2014Pages 1293-1300 RelatedInformation
Referência(s)